Alzheimer’s drugs market is steadily expanding as the global incidence of Alzheimer’s disease—characterized by cognitive decline and memory loss—continues to rise alongside aging populations. While traditional therapies like cholinesterase inhibitors and NMDA antagonists remain foundational for symptom management, the market is also witnessing growing interest in emerging disease-modifying treatments, such as monoclonal antibodies targeting amyloid and tau proteins.

According to Fortune Business Insights, the global Alzheimer’s drugs market was valued at USD 3.52 billion in 2022 and is projected to grow from USD 3.69 billion in 2023 to USD 5.21 billion by 2030, exhibiting a CAGR of 5.1% during the forecast period. In 2022, North America dominated the Alzheimer’s drugs market with a market share of 51.42%.

📌 Top Companies in the Alzheimer’s Drugs Market

• EISAI CO., LTD. (Japan)
• Novartis AG (Switzerland)
• Biogen Inc. (U.S.)
• H. Lundbeck A/S (Denmark)
• Otsuka Pharmaceutical Co., Ltd. (Japan)

Key Industry Development – July 2023

In July 2023, the U.S. Food and Drug Administration granted marketing approval to Leqembi (lecanemab‑irmb) for the treatment of early-stage Alzheimer’s disease. Leqembi is a monoclonal antibody that targets and reduces amyloid-beta plaques in the brain, representing a significant advancement in disease-modifying therapy.

📈 Key Market Drivers & Restraints

Drivers

• Rising Geriatric Population: The growing elderly demographic increases Alzheimer’s incidence, boosting demand for treatment.
• FDA Approvals: Groundbreaking approvals like Leqembi and Aduhelm fuel market growth.
• Increased Awareness & Funding: Government initiatives and public awareness campaigns encourage early diagnosis and treatment.
• Clinical Pipeline Expansion: Over 187 Alzheimer’s drug trials are ongoing as of early 2023.

Restraints

• High Clinical Attrition Rates: Many drug candidates fail in late-stage trials (e.g., gantenerumab), slowing market expansion.
• High Treatment Costs: Estimated annual cost per patient in the U.S. exceeds USD 300 billion collectively.